Loading...
LanzaTech’s Q4 2024 results reflected revenue challenges tied to delayed biorefining project timelines, while operating costs remained high, resulting in a wider net loss.
Revenue declined to $12.0 million from $20.5 million in Q4 2023 due to timing delays in large biorefining projects.
Net loss widened to $27.0 million from $18.7 million year-over-year.
Gross margin improved to 54% due to a favorable revenue mix including higher CarbonSmart sales.
Cash and investments dropped to $58.1 million from $89.1 million at the end of Q3 2024.
LanzaTech plans to refocus operations on global deployment but acknowledges ongoing financial challenges.
Visualization of income flow from segment revenue to net income